Does Rallies show 13F holders for VIR?

Yes. Rallies tracks hedge fund and 13F ownership data for VIR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is VIR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VIR. It does not provide personalized investment advice.

VIR (Vir Biotechnology, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Vir Biotechnology, Inc. Common Stock (VIR) is a publicly traded Healthcare sector company. As of May 21, 2026, VIR trades at $9.08 with a market cap of $1.48B and a P/E ratio of -2.83. VIR moved +4.10% today. Year to date, VIR is +53.37%; over the trailing twelve months it is +87.74%. Its 52-week range spans $4.16 to $14.45. Analyst consensus is strong buy with an average price target of $20.63. Rallies surfaces VIR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns VIR stock?

Hedge funds tracked by Rallies that own VIR include Orbimed Advisors, Panagora Asset, and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Vir Biotechnology, Inc. Common Stock.

VIR Key Metrics

Key financial metrics for VIR
Metric	Value
Price	$9.08
Market Cap	$1.48B
P/E Ratio	-2.83
EPS	$-3.12
Dividend Yield	0.03%
52-Week High	$14.45
52-Week Low	$4.16
Volume	24
Avg Volume	0
Revenue (TTM)	$65.50M
Net Income	$-442.72M
Gross Margin	0.00%

Top Hedge Funds Holding VIR

Orbimed Advisors holds 2.38M shares of VIR, changed +0.00% as of Dec 31, 2025.
Panagora Asset holds 375.35K shares of VIR, changed +1.09% as of Mar 31, 2026.
Farallon Capital holds 22.00K shares of VIR, changed +0.00% as of Mar 31, 2026.

Latest VIR News

Vir Biotechnology’s VIR-5500 Delivers 82% PSA50, 53% PSA90 and Secures Astellas Collaboration — Mar 5, 2026
Vir Biotechnology Secures $150 Million in $8.50 Share Public Offering — Feb 26, 2026
Vir Biotechnology Files Offering Registration with 30-Day Over-Allotment Option — Feb 24, 2026
Vir Biotech Shares Surge 35% and Ink $1.71B Astellas Collaboration — Feb 24, 2026
Vir Biotechnology Surges on $240M Cash Deal and up to $1.37B Milestones — Feb 24, 2026

Recent VIR Insider Trades

SATO VICKI L sold 22.00K (~$221.03K) on May 1, 2026.
De Backer Marianne sold 72.56K (~$664.35K) on Apr 6, 2026.
SATO VICKI L sold 22.00K (~$199.62K) on Apr 1, 2026.

VIR Analyst Consensus

9 analysts cover VIR: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.63.

Common questions about VIR

Who owns VIR stock?: Hedge funds tracked by Rallies that own VIR include Orbimed Advisors, Panagora Asset, and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Vir Biotechnology, Inc. Common Stock.
Does Rallies show 13F holders for VIR?: Yes. Rallies tracks hedge fund and 13F ownership data for VIR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is VIR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VIR. It does not provide personalized investment advice.